Phase II Win For Merck KGaA/Avillion Psoriasis Drug May Be Too Late
Sonelokinab Targets Both IL-17A and IL-17F
The German major is looking for a partner to advance its IL-17A/IL-17F nanobody sonelokinab for psoriasis but the search could be tricky given the strength of Novartis's Cosentyx and Eli Lilly's Taltz, while UCB's IL-17A and IL-17F inhibitor bimekizumab is likely to be approved soon.
You may also be interested in...
The coronavirus pandemic hurt the German group's healthcare division but helped the contract development and manufacturing activities of Merck's life sciences business.
Oncology is an area where the Swiss major has long been a dominant player, and Bill Anderson highlighted programs to Scrip which Roche hopes will help extend that dominance.
The Swiss major's pharma chief Bill Anderson tells Scrip that the goal for the firm over the next decade is to deliver twice as many medicines at a much lower cost to society.